Abstract
Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth, parturition and lactation. It has been implicated in the control of social behaviors and relationships, such as monogamy or promiscuous behaviors. The putative involvement of oxytocin in schizophrenia was first postulated following several pioneer reports of oxytocin use in schizophrenia and observations of increased oxytocin levels in the cerebrospinal fluid of schizophrenic patients, although this latter finding has subsequently been challenged. More recently, oxytocin plasma levels have been found to be decreased in schizophrenic individuals, particularly in those exhibiting hyponatremic polydipsia and emotional dysregulation. Some authors report that intranasal oxytocin administration to schizophrenic patients may reduce symptomatology. The aim of the present paper was to review studies investigating symptomatology, social cognition and emotion recognition changes in DSM-IV-TR schizophrenic patients, after administration of intranasal oxytocin at different doses. Literature search was conducted in March, 2012. PubMed and Scopus databases were used to find studies for inclusion in the systematic review. Oxytocin may represent an important novel adjunctive treatment for patients with schizophrenia. However, some limitations of current studies cannot be overlooked and further investigations are certainly needed.
Keywords: Intranasal oxytocin, schizophrenia, social cognition, emotions, review.
CNS & Neurological Disorders - Drug Targets
Title:The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
Volume: 12 Issue: 2
Author(s): Domenico De Berardis, Stefano Marini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomeis, Monica Mazza, Alessandro Valchera, Michele Fornaro, Marilde Cavuto, Venkataramanujam Srinivasan, Gianna Sepede, Giovanni Martinotti and Massimo Di Giannantonio
Affiliation:
Keywords: Intranasal oxytocin, schizophrenia, social cognition, emotions, review.
Abstract: Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth, parturition and lactation. It has been implicated in the control of social behaviors and relationships, such as monogamy or promiscuous behaviors. The putative involvement of oxytocin in schizophrenia was first postulated following several pioneer reports of oxytocin use in schizophrenia and observations of increased oxytocin levels in the cerebrospinal fluid of schizophrenic patients, although this latter finding has subsequently been challenged. More recently, oxytocin plasma levels have been found to be decreased in schizophrenic individuals, particularly in those exhibiting hyponatremic polydipsia and emotional dysregulation. Some authors report that intranasal oxytocin administration to schizophrenic patients may reduce symptomatology. The aim of the present paper was to review studies investigating symptomatology, social cognition and emotion recognition changes in DSM-IV-TR schizophrenic patients, after administration of intranasal oxytocin at different doses. Literature search was conducted in March, 2012. PubMed and Scopus databases were used to find studies for inclusion in the systematic review. Oxytocin may represent an important novel adjunctive treatment for patients with schizophrenia. However, some limitations of current studies cannot be overlooked and further investigations are certainly needed.
Export Options
About this article
Cite this article as:
Berardis Domenico De, Marini Stefano, Iasevoli Felice, Tomasetti Carmine, Bartolomeis Andrea de, Mazza Monica, Valchera Alessandro, Fornaro Michele, Cavuto Marilde, Srinivasan Venkataramanujam, Sepede Gianna, Martinotti Giovanni and Giannantonio Massimo Di, The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review, CNS & Neurological Disorders - Drug Targets 2013; 12 (2) . https://dx.doi.org/10.2174/1871527311312020012
DOI https://dx.doi.org/10.2174/1871527311312020012 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Etanercept for the Treatment of Dermatological Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease
Current Alzheimer Research Episodic Memory Impairment in Frontotemporal Dementia; A <sup>99m</sup>Tc- HMPAO SPECT Study
Current Alzheimer Research Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca<sup>2+</sup>]<sub>i</sub>, Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity
Current HIV Research Cybernetic Principles of Aging and Rejuvenation: The Buffering- Challenging Strategy for Life Extension
Current Aging Science Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Current Alzheimer Research Human Brain Nicotinic Receptors, their Distribution and Participation in Neuropsychiatric Disorders
Current Drug Targets - CNS & Neurological Disorders Detection of Amyloid-β Aggregates in Body Fluids: A Suitable Method for Early Diagnosis of Alzheimers Disease?
Current Alzheimer Research Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer’s Disease
Current Medicinal Chemistry Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes
Current Neurovascular Research General Anesthetics in Brain Injury: Friends or Foes?
Current Pharmaceutical Design Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders